The mechanism of carbamazepine aggravation of absence seizures

被引:70
|
作者
Liu, Lige
Zheng, Thomas
Morris, Margaret J.
Wallengren, Charlott
Clarke, Alison L.
Reid, Christopher A.
Petrou, Steven
O'Brien, Terence J.
机构
[1] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia
[2] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic 3050, Australia
[3] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic 3050, Australia
[4] Capital Univ Med Sci, Beijing Friendship Hosp, Beijing, Peoples R China
[5] Univ New S Wales, Dept Physiol & Pharmacol, Sydney, NSW, Australia
[6] Howard Florey Inst Expt Physiol & Med, Melbourne, Vic, Australia
关键词
D O I
10.1124/jpet.106.104968
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Carbamazepine (CBZ) aggravates many generalized seizures types, particularly absence seizures, but the mechanisms underlying this are poorly understood. GABA signaling within the reticular nucleus (Rt) and the ventrobasal complex (VB) of the thalamus is critical to the neurophysiology of absence seizures. The hypothesis that CBZ aggravates absence seizures by acting at the VB thalamus via a GABA(A) receptor-mediated mechanism was investigated in a genetic rat model, generalized absence epilepsy rats from Strasbourg (GAERS). Seizure activity was quantified by a 90-min electroencephalogram recording postdrug injection. Intracerebroventricular injections of CBZ (15 mu g in 4 mu l) resulted in seizure aggravation versus vehicle treatment, with a mean increase in seizure time of 40%. This indicates that CBZ acts directly, rather than via a metabolite, on the brain to aggravate seizures. Seizure aggravation also occurred following bilateral microinjection of CBZ (0.75 mu g in 0.2 mu l) into the VB (53%) but not following injection into the Rt (-9%). However, seizure aggravation was blocked when the GABA A receptor antagonist, bicuculline (BIC, 0.04 mu g in 0.2 mu l), was coinjected with CBZ into the VB. Injection of BIC alone (versus vehicle) into the VB also blocked seizure aggravation following systemic administration of CBZ ( 15 mg/kg i.p.). In vitro studies in Xenopus oocytes expressing recombinant GABA A receptors demonstrated that CBZ produced a dose-dependent potentiation of the GABA current at a physiological relevant concentration range (1-100 mu M). These data demonstrate that CBZ acts at the VB thalamus to aggravate absence seizures in GAERS and that activation of GABA A receptors is critical to this effect.
引用
收藏
页码:790 / 798
页数:9
相关论文
共 50 条
  • [31] Aggravation of atonic seizures by rufinamide: A case report
    Bektas, Gonca
    Caliskan, Mine
    Aydin, Ali
    Yildiz, Edibe Pembegul
    Tatli, Burak
    Aydinli, Nur
    Ozmen, Meral
    BRAIN & DEVELOPMENT, 2016, 38 (07): : 654 - 657
  • [32] Lacosamide and myoclonic seizures: what is the risk of aggravation?
    Bosak, Magdalena
    Wezyk, Kamil
    Slowik, Agnieszka
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2021, 55 (01) : 107 - 109
  • [33] ABSENCE SEIZURES
    不详
    LANCET, 1975, 2 (7948): : 1292 - 1292
  • [34] Aggravation of focal epileptic seizures by antiepileptic drugs
    Elger, CE
    Bauer, J
    Scherrmann, J
    Widman, G
    EPILEPSIA, 1998, 39 : S15 - S18
  • [35] Symptomatic absence seizures, the least known causation of absence seizures
    Carrera-Garcia, Laura
    Malaga-Dieguez, Ignacio
    Blanco-Lago, Raquel
    Diaz-Baamonde, Alba
    Santovena-Gonzalez, Luis
    Gonzalez-Rato, Jesus
    REVISTA DE NEUROLOGIA, 2017, 65 (06) : 263 - 267
  • [36] CARBAMAZEPINE AND OXCARBAZEPINE TRIGGERED EPILEPTIC NEGATIVE MYOCLONUS AGGRAVATION IN CHILDHOOD
    Mukhin, K. Y.
    Mironov, M. B.
    EPILEPSIA, 2012, 53 : 79 - 79
  • [38] CHILDHOOD SEIZURES AFTER CARBAMAZEPINE - REPLY
    SNEAD, OC
    HOSEY, LC
    NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (13): : 853 - 853
  • [39] Does carbamazepine really exacerbate seizures?
    Huang, XM
    D'Cruz, O
    ANNALS OF NEUROLOGY, 2000, 48 (03) : 520 - +
  • [40] Carbamazepine induced seizures and ventricular dysrhythmias
    Levine, Michael
    Bosak, Adam
    Yee, Berne
    An Tran
    CLINICAL TOXICOLOGY, 2013, 51 (07) : 653 - 654